233 related articles for article (PubMed ID: 34789568)
1. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
Naert T; Tulkens D; Van Nieuwenhuysen T; Przybyl J; Demuynck S; van de Rijn M; Al-Jazrawe M; Alman BA; Coucke PJ; De Leeneer K; Vanhove C; Savvides SN; Creytens D; Vleminckx K
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34789568
[TBL] [Abstract][Full Text] [Related]
2. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
6. β-catenin S45F mutation results in apoptotic resistance.
Braggio D; Zewdu A; Londhe P; Yu P; Lopez G; Batte K; Koller D; Costas Casal de Faria F; Casadei L; Strohecker AM; Lev D; Pollock RE
Oncogene; 2020 Aug; 39(34):5589-5600. PubMed ID: 32651460
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Wnt/Beta catenin signalling in desmoid tumors.
Tejpar S; Michils G; Denys H; Van Dam K; Nik SA; Jadidizadeh A; Cassiman JJ
Acta Gastroenterol Belg; 2005; 68(1):5-9. PubMed ID: 15832580
[TBL] [Abstract][Full Text] [Related]
8. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
[TBL] [Abstract][Full Text] [Related]
9. Adenomatous Polyposis Coli as a Major Regulator of Human Embryonic Stem Cells Self-Renewal.
Preisler L; Ben-Yosef D; Mayshar Y
Stem Cells; 2019 Dec; 37(12):1505-1515. PubMed ID: 31461190
[TBL] [Abstract][Full Text] [Related]
10. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4.
Lu H; Sun J; Wang F; Feng L; Ma Y; Shen Q; Jiang Z; Sun X; Wang X; Jin H
Cell Death Dis; 2013 Aug; 4(8):e776. PubMed ID: 23949225
[TBL] [Abstract][Full Text] [Related]
12. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
13. [Construction of EZH2 Knockout Animal Model by CRISPR/Cas9 Technology].
Meng F; Zhao D; Zhou Q; Liu Z
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):358-364. PubMed ID: 29764585
[TBL] [Abstract][Full Text] [Related]
14. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis.
Chen Y; Pan K; Wang P; Cao Z; Wang W; Wang S; Hu N; Xue J; Li H; Jiang W; Li G; Zhang X
J Biol Chem; 2016 Jun; 291(24):12688-12705. PubMed ID: 27129219
[TBL] [Abstract][Full Text] [Related]
15. Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future.
Mao XY; Dai JX; Zhou HH; Liu ZQ; Jin WL
Oncotarget; 2016 May; 7(22):33461-71. PubMed ID: 26993776
[TBL] [Abstract][Full Text] [Related]
16. Live-cell imaging reveals the dynamics of PRC2 and recruitment to chromatin by SUZ12-associated subunits.
Youmans DT; Schmidt JC; Cech TR
Genes Dev; 2018 Jun; 32(11-12):794-805. PubMed ID: 29891558
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
Liao Y; Chen CH; Xiao T; de la Peña Avalos B; Dray EV; Cai C; Gao S; Shah N; Zhang Z; Feit A; Xue P; Liu Z; Yang M; Lee JH; Xu H; Li W; Mei S; Pierre RS; Shu S; Fei T; Duarte M; Zhao J; Bradner JE; Polyak K; Kantoff PW; Long H; Balk SP; Liu XS; Brown M; Xu K
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35031563
[TBL] [Abstract][Full Text] [Related]
18. Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways.
Liu L; Xiao B; Hirukawa A; Smith HW; Zuo D; Sanguin-Gendreau V; McCaffrey L; Nam AJ; Muller WJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303010120. PubMed ID: 37549258
[TBL] [Abstract][Full Text] [Related]
19. A first-generation pediatric cancer dependency map.
Dharia NV; Kugener G; Guenther LM; Malone CF; Durbin AD; Hong AL; Howard TP; Bandopadhayay P; Wechsler CS; Fung I; Warren AC; Dempster JM; Krill-Burger JM; Paolella BR; Moh P; Jha N; Tang A; Montgomery P; Boehm JS; Hahn WC; Roberts CWM; McFarland JM; Tsherniak A; Golub TR; Vazquez F; Stegmaier K
Nat Genet; 2021 Apr; 53(4):529-538. PubMed ID: 33753930
[TBL] [Abstract][Full Text] [Related]
20. Assessment of endostatin gene therapy for familial adenomatous polyposis-related desmoid tumors.
Martinico SC; Jezzard S; Sturt NJ; Michils G; Tejpar S; Phillips RK; Vassaux G
Cancer Res; 2006 Aug; 66(16):8233-40. PubMed ID: 16912203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
